{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:27:45Z","timestamp":1770326865273,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,3]],"date-time":"2019-02-03T00:00:00Z","timestamp":1549152000000},"content-version":"am","delay-in-days":278,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["81470363"],"award-info":[{"award-number":["81470363"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["81670188"],"award-info":[{"award-number":["81670188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan University Faculty Start Fund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bone.2018.01.021","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T06:47:56Z","timestamp":1517640476000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Young female patients with multiple myeloma have low occurrence of osteolytic lesion"],"prefix":"10.1016","volume":"110","author":[{"given":"Danfeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingcao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2018.01.021_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bone.2018.01.021_bb0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bone.2018.01.021_bb0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-3-319-40320-5_14","article-title":"Bone Disease in Multiple Myeloma","volume":"169","author":"Eda","year":"2016","journal-title":"Cancer Treat. Res."},{"issue":"3","key":"10.1016\/j.bone.2018.01.021_bb0020","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.14827","article-title":"Guidelines for the use of imaging in the management of patients with myeloma","volume":"178","author":"Chantry","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.bone.2018.01.021_bb0025","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","article-title":"Biology of osteoclast activation in cancer","volume":"19","author":"Roodman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bone.2018.01.021_bb0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.bone.2018.01.021_bb0035","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev."},{"issue":"13","key":"10.1016\/j.bone.2018.01.021_bb0040","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bone.2018.01.021_bb0045","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bone.2018.01.021_bb0050","article-title":"Mechanisms of bone destruction in multiple myeloma","volume":"26","author":"Terpos","year":"2017","journal-title":"Eur. J. Cancer Care"},{"issue":"10","key":"10.1016\/j.bone.2018.01.021_bb0055","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2006-04-017087","article-title":"MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma","volume":"108","author":"Masih-Khan","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2018.01.021_bb0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.bone.2018.01.021_bb0065","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bone.2018.01.021_bb0070","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"7339","key":"10.1016\/j.bone.2018.01.021_bb0075","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bone.2018.01.021_bb0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/gcc.20668","article-title":"A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect","volume":"48","author":"Agnelli","year":"2009","journal-title":"Genes Chromosom. Cancer"},{"issue":"4","key":"10.1016\/j.bone.2018.01.021_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.bone.2018.01.021_bb0090","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bone.2018.01.021_bb0095","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bone.2018.01.021_bb0100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.bone.2018.01.021_bb0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-1-4939-0512-6_9","article-title":"A description of the Molecular Signatures Database (MSigDB) Web site","volume":"1150","author":"Liberzon","year":"2014","journal-title":"Methods Mol. Biol."},{"issue":"8","key":"10.1016\/j.bone.2018.01.021_bb0110","first-page":"711","article-title":"The value of chest computerized tomography in evaluation of bone disease and clinical prognosis of multiple myeloma","volume":"54","author":"Tang","year":"2015","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"11","key":"10.1016\/j.bone.2018.01.021_bb0115","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bone.2018.01.021_bb0120","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","article-title":"Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability","volume":"13","author":"Hannon","year":"1998","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2018.01.021_bb0125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"32","key":"10.1016\/j.bone.2018.01.021_bb0130","doi-asserted-by":"crossref","first-page":"28936","DOI":"10.1074\/jbc.M504761200","article-title":"Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine\/threonine kinases","volume":"280","author":"Valiente","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bone.2018.01.021_bb0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1868-7083-6-16","article-title":"Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma","volume":"6","author":"Piras","year":"2014","journal-title":"Clin. Epigenetics"},{"issue":"1","key":"10.1016\/j.bone.2018.01.021_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2011.04.015","article-title":"Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN","volume":"308","author":"Heo","year":"2011","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bone.2018.01.021_bb0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12185-010-0604-y","article-title":"Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma","volume":"92","author":"Wang","year":"2010","journal-title":"Int. J. Hematol."},{"issue":"34","key":"10.1016\/j.bone.2018.01.021_bb0150","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1038\/sj.onc.1205650","article-title":"PTEN, but not SHIP and SHIP2, suppresses the PI3K\/Akt pathway and induces growth inhibition and apoptosis of myeloma cells","volume":"21","author":"Choi","year":"2002","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.bone.2018.01.021_bb0155","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood.V96.10.3560","article-title":"Loss of PTEN expression leading to high Akt activation in human multiple myelomas","volume":"96","author":"Hyun","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bone.2018.01.021_bb0160","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3109\/10428194.2011.647311","article-title":"Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration","volume":"53","author":"Wang","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.bone.2018.01.021_bb0165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.leukres.2005.07.008","article-title":"Analysis of PTEN deletions and mutations in multiple myeloma","volume":"30","author":"Chang","year":"2006","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.bone.2018.01.021_bb0170","first-page":"168","article-title":"Bisphosphonates and statins inhibit expression and secretion of MIP-1alpha via suppression of Ras\/MEK\/ERK\/AML-1A and Ras\/PI3K\/Akt\/AML-1A pathways","volume":"5","author":"Tsubaki","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"14","key":"10.1016\/j.bone.2018.01.021_bb0175","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1158\/0008-5472.CAN-08-4285","article-title":"Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235","volume":"69","author":"McMillin","year":"2009","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bone.2018.01.021_bb0180","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.leukres.2014.12.015","article-title":"The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma","volume":"39","author":"Martin","year":"2015","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.bone.2018.01.021_bb0185","first-page":"1434","article-title":"Estrogen receptors in human myeloma cells","volume":"60","author":"Otsuki","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2018.01.021_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1476-4598-6-59","article-title":"Estrogenic or antiestrogenic therapies for multiple myeloma?","volume":"6","author":"Sola","year":"2007","journal-title":"Mol. Cancer"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218300218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218300218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:40:01Z","timestamp":1757612401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328218300218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":38,"alternative-id":["S8756328218300218"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2018.01.021","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Young female patients with multiple myeloma have low occurrence of osteolytic lesion","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2018.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}